CRSP - Editas gains on Vertex licensing deal for gene editing tech
2023-12-13 09:33:01 ET
More on Editas, Vertex, etc.
- Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript)
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)
- Vertex gains as diabetic pain therapy succeeds in mid-stage trial
- FDA approves Vertex, CRISPR gene therapy for sickle cell disease (update)
For further details see:
Editas gains on Vertex licensing deal for gene editing tech